Zacks Investment Research Upgrades Medifast Inc (MED) to Buy

Zacks Investment Research Upgrades Medifast Inc (MED) to Buy


The firm currently has $33.00 target price on the stock. According to Zacks, "Medifast Inc has one operating subsidiary, Jason Pharmaceuticals, Inc, its manufacturing arm.



from Biotech News